Canaccord analyst Jason Mills raised his price target on CryoLife to $36 from $28 following its beat and raise Q2 results. The analyst noted its solid execution and improving underlying business trends. He also noted its acquisitions are tracking ahead of plan. Mills reiterated his Buy rating on CryoLife shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.